Press Release: PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500
MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such…
Press Release: PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 - Newscast
Thu, 13 Feb 2025 21:05:00 GMT "Looking ahead to 2025, while the macro environment remains uncertain, I believe PacBio can return to growth and expand market share as the Vega benchtop platform and SPRQ chemistry enable ...
Thu, 13 Feb 2025 08:05:00 GMT "Looking ahead to 2025, while the macro environment remains uncertain, I believe PacBio can return to growth and expand market share as the Vega benchtop platform and SPRQ chemistry enable more ...
Thu, 13 Feb 2025 08:05:00 GMT Loss on extinguishment of debt is related to the exchange of a portion of PacBio's 1.50% Convertible Senior Notes due 2028 for PacBio's 1.375% Convertible Senior Notes due 2030. Gain on debt ...
Mon, 03 Feb 2025 01:05:00 GMT PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Forward Looking Statements This press release may contain “forward-looking statements” within the ...
